Latest Dilution News

Vanadium Resources raises about A$1 million through a placement to fund studies and site agreements for its Steelpoortdrift Vanadium Project and next-gen V-Iron Plant, aiming to supply Western critical mineral markets.

Entropy Neurodynamics has unveiled a striking 75% response rate in a small Phase 2a trial of its oral psilocybin therapy for treatment-resistant irritable bowel syndrome, far surpassing existing treatments and validating its gut-brain axis approach.

Cynata Therapeutics has secured A$1.5 million through an institutional placement priced at a 22.5% discount, aiming to extend its cash runway ahead of pivotal Phase 3 and Phase 2 trial results expected in May and June 2026.

Nexsen Limited teams with Universiti Malaya to launch a joint research facility aiming to develop a rapid biosensor detecting E. coli and Salmonella simultaneously, addressing a critical food safety gap in Southeast Asia.

Alchemy Resources has finalised the sale of its Karonie and Lake Rebecca projects to Forrestania Resources, securing over 7.7 million shares and a royalty, while gearing up for copper exploration in New South Wales.

Pacgold Limited has poured its first gold doré bar from the White Dam Gold Project, signalling its shift from exploration to production and initiating cash flow to support growth.

Key Petroleum Ltd has wrapped up the last 3% tranche of its share placement, raising nearly $59,000 and exhausting its 15% ASX placement limit. The fresh capital is earmarked for asset acquisitions, development, and working capital.

Toro Energy shareholders face a pivotal vote on a takeover scheme by IsoEnergy, offering a near 80% premium and access to a diversified uranium portfolio across Australia, Canada, and the US.

Fat Prophets Global Contrarian Fund (ASX: FPC) has launched an on-market buy-back of its ordinary shares, set to run from May 2026 to May 2027, signalling a fresh phase in its capital management strategy.

Jayride Group continues its pivot to a SaaS mobility platform across Australasia and Southeast Asia, managing tight cash flow and planning a capital raise to sustain operations and support ASX reinstatement.

Resmed delivered a robust Q3 FY2026 with 11% revenue growth, margin expansion, and a 21% jump in non-GAAP EPS, while announcing a new U.S. distribution centre and a $0.60 dividend.

Contact Energy is set for a leadership shift as Chair Rob McDonald retires after eight transformative years, handing the reins to director Jon Macdonald, whose governance experience promises continuity amid ongoing renewable expansion.